Prevalence of prediabetes and undiagnosed type 2 diabetes in France: Results from the national survey ESTEBAN, 2014-2016.


Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 28 01 2020
revised: 27 05 2020
accepted: 04 06 2020
pubmed: 12 6 2020
medline: 18 9 2020
entrez: 12 6 2020
Statut: ppublish

Résumé

To assess the prevalence of prediabetes, undiagnosed diabetes and diagnosed diabetes in France, among adults between 2014 and 2016 using data from the nationwide Esteban survey. National cross-sectional study conducted between 2014 and 2016 in metropolitan France. Individuals aged 18 to 74 were recruited with a 3-stage geographic sampling. They completed two face-to-face interviews, filled in a self-administered questionnaire and underwent a medical examination with the collection of biological samples. Their data were linked to the National Health Data System to identify anti-diabetic drugs reimbursement. Prediabetes and undiagnosed diabetes were defined as no diagnosis of diabetes and 6.1 mmol/l ≤ Fasting Plasma Glucose (FPG) < 7.0 mmol/l for prediabetes and FPG ≥ 7.0 mmol/l for undiagnosed diabetes. Non-pharmacologically treated diabetes and pharmacologically treated diabetes were defined as self-reported diabetes without or with self-reported or reimbursed antidiabetic medication, respectively. Estimated prevalence were weighted to take into account survey design and non-response. The ESTEBAN survey recruited 3476 adults, 2270 were included in this analysis. The weighted prevalence was 1.7% [1.1 - 2.4] for undiagnosed diabetes (men: 2.7%, women; 0.9%), 9.9% [8.3 - 11.5] for prediabetes (men: 13.2%, women: 7.0%), 5.7% [4.3 - 7.1] for diagnosed diabetes. Among the diagnosed cases, 79% were pharmacologically treated. Among all diabetes cases, 23% were undiagnosed. The prevalence of undiagnosed diabetes and prediabetes is increasing in France. Our results highlight the need to increase primary prevention and reinforce secondary prevention of diabetes.

Identifiants

pubmed: 32526264
pii: S0168-8227(20)30502-7
doi: 10.1016/j.diabres.2020.108252
pii:
doi:

Types de publication

Historical Article Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108252

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Grégory Lailler (G)

Santé Publique France, Department of Non-Communicable Diseases and Trauma.

Clara Piffaretti (C)

Santé Publique France, Department of Non-Communicable Diseases and Trauma.

Sonsoles Fuentes (S)

Santé Publique France, Department of Non-Communicable Diseases and Trauma.

Hadja Djessira Nabe (HD)

Santé Publique France, Department of Non-Communicable Diseases and Trauma.

Amivi Oleko (A)

Santé Publique France, Department of Environmental and Occupational Health, Saint-Maurice, France.

Emmanuel Cosson (E)

Department of Diabetology, Endocrinology and Metabolism, CRNH-IdF, CINFO, Paris 13 University, Sorbonne Paris cité, Avicenne Hospital, AP-HP, 93000 Bobigny, France; UMR U1153 Inserm, U1125 Inra, Cnam, Paris 13 University, Sorbonne Paris cité, 93000 Bobigny, France.

Sandrine Fosse-Edorh (S)

Santé Publique France, Department of Non-Communicable Diseases and Trauma. Electronic address: Sandrine.fosse@santepubliquefrance.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH